Consider participating in the OUTLAST study for patients who are seeking treatment for meth addiction.

iStock-1266839025.jpg

Your participation in the OUTLAST study is confidential and protected.

ABOUT OUTLAST

Currently there are no approved medications for the treatment of methamphetamine (meth) use disorder (MUD). OUTLAST is a Phase 2 study evaluating the safety and effectiveness of IXT-m200, an investigational drug, in treatment-seeking individuals who actively use meth.

 

We are not affiliated with any law enforcement agency. Your participation in the OUTLAST study is confidential and protected.

The purpose of the OUTLAST study is to see if IXT-m200 will decrease relapses, improve the signs and symptoms associated with meth use, and improve the quality of life in treatment-seeking individuals.

iStock-1359496884.jpg

WHO CAN JOIN OUTLAST

You may be eligible to participate in the OUTLAST study if you:

  • Are at least 18 years of age

  • Are seeking treatment for meth addiction

  • Have a positive meth drug test during screening

  • Are willing to take saliva drug screens during participation

  • Are willing to share information daily regarding drug use

ABOUT PARTICIPATION IN OUTLAST

Before participating in OUTLAST, you will be screened through a series of steps, to see if you qualify. If you are eligible, you will begin to receive the study drug. The study drug will be administered through an IV line over 30 minutes. You will receive 6 doses of either IXT-m200 or placebo, spaced 4 weeks apart. You will be randomly assigned, like by the flip of a coin, to either IXT-m200 or placebo. The group of patients assigned to IXT-m200 will be compared to the group of patients assigned to placebo to help researchers better understand the effects of IXT-m200. The study team will follow all patients closely throughout study participation. All participants will follow the same visit schedule and will be asked to complete the same study procedures.

As part of the study, you will be asked to record your drug use daily in a smartphone app. You will also use the app to record your saliva drug tests. Remember, your study participation is confidential, and data collected during the study will not be reported to any law enforcement agency. You will also use the app to connect with your recovery coach. Your recovery coach has been where you are today. They are in long-term recovery from their own drug use and know what you are going through. Your recovery coach will be available for a phone and/or video call once per week for the first 3 months and beyond. In addition to the scheduled calls, your recovery coach will be available by text during working hours.

 

iStock-1359496843.jpg

OUTLAST participation is planned for approximately 8 months, and it includes about 10 study visits. The investigational drug, study-related procedures, and doctor visits will be provided at no cost. You will receive some compensation for your participation.

Volunteers are an essential part of developing new medications. We know the decision to participate is a personal one. Thank you for considering OUTLAST.

For more information about OUTLAST or to see if you qualify, text OUTLAST to (844) 400-METH. A member of the study team will contact you within 24 hours. You may also contact the study team nearest you directly to discuss OUTLAST eligibility.

OUTLAST Centers Near You

ARKANSAS

 Bentonville, AR

 Pillar Clinical Research

 Fayz Hudefi, MD, Principal Investigator

 Eric Foster, Study Coordinator

 (479) 367-2688

 efoster@pillarhc.com

ARKANSAS

 Little Rock, AR

 Woodlands International Research Group

 George Konis, MD, Principal Investigator

 Polina Thomas, Study Coordinator

 (501) 221-8681

 pthomas@ergclinical.com

ARIZONA

 Phoenix, AZ

 Alea Research

 Jelena Kunovac, MD, Principal Investigator

 Angel Goewey, Study Coordinator

 (602) 562-7000

 agoewey@alearesearchphoenix.com

CALIFORNIA

 San Diego, CA

 Artemis Institute for Clinical Research

 Eric Chavez, MD, Principal Investigator

 Freia Canals Cistero, Study Coordinator

 (858) 278-3647 x130

 fcanalscistero@artemis-research.com

ILLINOIS

 Lincolnwood, IL

 Pillar Clinical Research

 Roueen Rafeyan, MD, Principal Investigator

 Dennis Waclawik, Study Coordinator

 (224) 534-7332

 dwaclawik@pillarhc.com

NEVADA

 Las Vegas, NV

 Altea Research Institute

 Mustafa Rawaf, DO, Principal Investigator

 Amanda Brown, Patient Recruitment Manager

 (702) 527-7401

 abrown@altearesearch.com

OHIO

 Dayton, OH

 Midwest Clinical Research Center

 Otto Dueno, MD, Principal Investigator

 Marcus McCarty-Towers, Study Coordinator

 (937) 424-1050

 recruitmentMCRC@ergclinical.com

OKLAHOMA

 Oklahoma City, OK

 Pahl Pharmaceutical Professionals, LLC

 Gita Pujari, MD, Principal Investigator

 Mark Pahl, Study Coordinator

 (405) 525-2222

 mpahl@pprtrials.com

TEXAS

 Richardson, TX

 Pillar Clinical Research

 Scott Bartley, MD, Principal Investigator

 Dana Siler, Study Coordinator

 (214) 396-4844

 dsiler@pillarhc.com

This study is being sponsored by InterveXion Therapeutics, LLC